LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Simulations Plus Inc

Open

BrancheGesundheitswesen

14.14 2.09

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

13.67

Max

14.25

Schlüsselkennzahlen

By Trading Economics

Einkommen

-70M

-67M

Verkäufe

-2.1M

20M

KGV

Branchendurchschnitt

48.528

35.733

Dividendenrendite

0.48

Gewinnspanne

-330.585

Angestellte

243

EBITDA

-79M

-74M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+67.63% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.48%

3.13%

Nächstes Ergebnis

22. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-66M

285M

Vorheriger Eröffnungskurs

12.05

Vorheriger Schlusskurs

14.14

Nachrichtenstimmung

By Acuity

50%

50%

173 / 371 Ranking in Healthcare

Simulations Plus Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Sept. 2025, 23:59 UTC

Akquisitionen, Fusionen, Übernahmen

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8. Sept. 2025, 22:02 UTC

Wichtige Markttreiber

Microsoft Signs $17.4 Billion AI Deal With Nebius

8. Sept. 2025, 17:01 UTC

Wichtige Markttreiber

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8. Sept. 2025, 17:01 UTC

Wichtige Markttreiber

Tron Shares Rise After New Investment From Bravemorning

8. Sept. 2025, 16:14 UTC

Wichtige Markttreiber

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8. Sept. 2025, 16:13 UTC

Wichtige Markttreiber

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8. Sept. 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Sept. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8. Sept. 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8. Sept. 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8. Sept. 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8. Sept. 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8. Sept. 2025, 21:47 UTC

Wichtige Markttreiber

Microsoft Signs $17.4B AI Deal With Nebius

8. Sept. 2025, 21:33 UTC

Akquisitionen, Fusionen, Übernahmen

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8. Sept. 2025, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8. Sept. 2025, 21:19 UTC

Akquisitionen, Fusionen, Übernahmen

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8. Sept. 2025, 21:18 UTC

Akquisitionen, Fusionen, Übernahmen

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8. Sept. 2025, 20:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

8. Sept. 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8. Sept. 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8. Sept. 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8. Sept. 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Sept. 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8. Sept. 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8. Sept. 2025, 16:59 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8. Sept. 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8. Sept. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8. Sept. 2025, 16:16 UTC

Ergebnisse

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8. Sept. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. Sept. 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Simulations Plus Inc Prognose

Kursziel

By TipRanks

67.63% Vorteil

12-Monats-Prognose

Durchschnitt 23.2 USD  67.63%

Hoch 31 USD

Tief 15 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Simulations Plus Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

4

Buy

3

Halten

0

Sell

Stimmung

By Acuity

173 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat